You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Claims for Patent: 12,263,153

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,263,153

Title:	Pharmaceutical composition, methods for treating and uses thereof
Abstract:	The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.
Inventor(s):	Maximilian von EYNATTEN, Uli Christian BROEDL, Hans-Juergen Woerle
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US17/831,460
Patent Claims:	1. A method for reducing the risk of cardiovascular death in a patient with chronic kidney disease, the method comprising administering a pharmaceutically effective amount of empagliflozin to the patient. 2. A method for treating, reducing the risk of or slowing the progression of chronic kidney disease and reducing the risk of cardiovascular death in a patient with chronic kidney disease, the method comprising administering a pharmaceutically effective amount of empagliflozin to the patient. 3. The method according to claim 1, wherein the cardiovascular death is due to fatal myocardial infarction or fatal stroke. 4. The method according to claim 1, wherein the cardiovascular death is due to sudden death or heart failure death. 5. The method of claim 1, wherein the patient has moderately to severely decreased renal function. 6. The method of claim 1, wherein the patient has elevated albuminuria levels ≥200 mg/g. 7. The method of claim 1, wherein the patient has an estimated glomerular filtration rate (eGFR)≥20 to <45 mL/min/1.73 m2. 8. The method of claim 1, wherein the patient has an estimated glomerular filtration rate (eGFR)≥20 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio (UACR) ≥200 mg/g. 9. The method of claim 1, wherein the patient has an eGFR≥45 and <90 ml/min/1.73m2 and a urinary albumin-to-creatinine ratio (UACR)≥200 mg/g. 10. The method of claim 1, wherein the patient is treated with a renin-angiotensin-aldosterone system (RAAS) inhibitor. 11. The method of claim 1, wherein the patient is treated with an Angiotensin-Converting Enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB). 12. The method of claim 1, wherein the patient is a non-diabetic patient. 13. The method of claim 1, wherein the patient is a non-diabetic and non-prediabetic patient. 14. The method of claim 1, wherein the patient is a patient with pre-diabetes or a patient with type 2 or type 1 diabetes mellitus. 15. The method of claim 1, wherein empagliflozin is administered at a dose in a range from 1 mg to 25 mg. 16. The method of claim 1, wherein empagliflozin is administered at a dose of 10 mg or 25 mg. 17. The method of claim 1, wherein empagliflozin is administered once daily to the patient. 18. The method of claim 2, wherein the patient has moderately to severely decreased renal function. 19. The method of claim 2, wherein the patient has elevated albuminuria levels ≥200 mg/g. 20. The method of claim 2, wherein the patient has an estimated glomerular filtration rate (eGFR)≥20 to <45 mL/min/1.73 m2. 21. The method of claim 2, wherein the patient has an estimated glomerular filtration rate (eGFR)≥20 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio (UACR)≥200 mg/g. 22. The method of claim 2, wherein the patient has an estimated glomerular filtration rate (eGFR)≥45 and <90 ml/min/1.73m2 and a urinary albumin-to-creatinine ratio (UACR)≥200 mg/g. 23. The method of claim 2, wherein the patient is treated with a renin-angiotensin-aldosterone system (RAAS) inhibitor. 24. The method of claim 2, wherein the patient is treated with an Angiotensin-Converting Enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB). 25. The method of claim 2, wherein the patient is a non-diabetic patient. 26. The method of claim 2, wherein the patient is a non-diabetic and non-prediabetic patient. 27. The method of claim 2, wherein the patient is a patient with pre-diabetes or a patient with type 2 or type 1 diabetes mellitus. 28. The method of claim 2, wherein empagliflozin is administered at a dose in a range from 1 mg to 25 mg. 29. The method of claim 2, wherein empagliflozin is administered at a dose of 10 mg or 25 mg. 30. The method of claim 2, wherein empagliflozin is administered once daily to the patient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.